BCL2 and B-cell chronic lymphocytic leukemia: In particular, Deng J. et al. (7) studied the cell’s proximity to the apoptotic threshold by BH3 profiling, showing that both ibrutinib and acalabrutinib increase the CLL cell’s dependence on BCL-2, thereby enhancing the sensitivity of BCL2 inhibition.